Filer	Title/Relationship	Filing Date	Planned Shares	Est. Value
Thomasian Harry Jr.	Officer	2026-07-01	171K shares	$949K
Sabzevari Helen	Officer, Director	2026-06-29	347K shares	$2.04M
Shah Rutul R	Officer	2026-06-29	43K shares	$251K
Thomasian Harry Jr.	Officer	2026-06-29	29K shares	$165K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding PRECIGEN INC (PGEN)?

Major stakeholders currently include Patient Capital Management, LLC ($69.0M), BlackRock, Inc. ($58.9M), State Street CORP ($42.1M). Based on the latest 13F filings, there are a total of 204 tracked investment funds and institutions maintaining positions in PGEN.

What is the overall institutional sentiment toward PGEN recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $52.4M, driven by 108 managers accumulating shares while 66 reduced their exposure.

Which institutions have been selling or reducing their PGEN positions?

In the latest period, 48 funds trimmed their holdings, and 18 managers completely exited their positions. The aggregate reported sell value was $286.1M.

Are there any notable investors adding PGEN to their portfolios?

Yes, buying activity remains notable. 38 institutions opened new positions in {ticker}, and 70 existing holders added to their shares. The total reported buy value for the quarter amounted to $300.0M.